bizalimogene ralaplasmid (VGX-3100) / Inovio, ApolloBio  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bizalimogene ralaplasmid (VGX-3100) / Inovio
REVEAL 1, NCT03185013 / 2016-002761-63: (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Completed
3
201
Europe, US, RoW
VGX-3100, Placebo, Electroporation (EP)
Inovio Pharmaceuticals
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
07/20
04/21
NCT03721978 / 2018-004114-17: REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Completed
3
203
Europe, US, RoW
VGX-3100, Placebo, CELLECTRAâ„¢-5PSP
Inovio Pharmaceuticals
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
08/22
09/22

Download Options